Delivery Order SPE2DB22D2006-SPE2DB25FW3GR
- Not listed
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This contract, valued at $19,707.30, represents a competitive award with firm fixed pricing and no set-aside designation. The delivery order is scheduled for completion by August 12, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. As a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units, with a contract ceiling value of $21,872.95. This competitively awarded, firm fixed-price delivery order is set to be completed by July 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $44,543.69 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a $10,027.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. The contract, with an ultimate completion date of August 8, 2025, represents a pharmaceutical delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order is not set-aside and was competitively awarded. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $21,125.75 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This is a non-set-aside competitive award with an ultimate completion date of August 15, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary distribution operations. As a child order under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,660.97 to AmerisourceBergen Drug Corp for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was issued on August 5, 2025, with an ultimate completion date of August 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Descovy 200-25 mg tablets in a 30-count unit configuration, valued at $8,022.27. This firm fixed price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by July 22, 2025. The contract reflects AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran healthcare systems, with performance occurring at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30, with a contract ceiling value of $28,667.28. This is a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $27,254.12, represents a non-competitive set-aside award with an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $71,609.11 for Descovy 200-25 mg tablets (30-count units) under a firm fixed price contract. This non-set-aside award, effective August 1, 2025 with an ultimate completion date of August 4, 2025, represents a pharmaceutical supply delivery to support federal medical procurement needs. The delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3GRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $84,036.28 and is set to conclude on August 12, 2025. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. This parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor for medical procurement serving military and veteran healthcare systems. The company demonstrates substantial capability in fulfilling federal pharmaceutical supply requirements through its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's status as a primary vendor for the Defense Health Agency and other government healthcare systems, combined with its consistent receipt of competitively awarded delivery orders, reflects its established position in supporting the Department of Defense's pharmaceutical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $84.0k | 8/11/25 |